Home / Health / Pfizer wins initial US hearing over Zoloft birth-defect risk

Pfizer wins initial US hearing over Zoloft birth-defect risk


(Reuters) – Pfizer Inc scored a pivotal feat Friday
when it was privileged of guilt in a initial U.S. trial
involving claims that a calmative Zoloft can means birth
defects in children innate to women who take a drug while
pregnant.

Plaintiff Kristyn Pesante claimed that Pfizer unsuccessful to warn
that regulating Zoloft during pregnancy could means birth defects and
sought indemnification after her son was innate with a rare, serious
congenital heart problem.

Following a week-long hearing in St. Louis, Missouri, jurors
deliberated quickly before clearing Pfizer of liability,
according to a Pfizer mouthpiece Neha Wadhwa. Pesante had
sought both saving and punitive damages, accusing Pfizer
of downplaying Zoloft’s risks in sequence to boost sales.

Hundreds of lawsuits observant Zoloft can lead to cardiac and
other birth defects have been filed in U.S. state and federal
courts. While not contracting on a other cases, Friday’s verdict
is “particularly significant” since Pesante’s was a first
case comparison by plaintiffs for hearing and featured most of the
same medical justification and theories underpinning other cases
across a country, Wadhwa said.

Pesante’s 2012 lawsuit pronounced that Pfizer touted Zoloft as a
treatment for basin in profound women that had a reduce risk
of side effects than identical drugs. She pronounced she took a drug
during her initial trimester and was not wakeful during a time of the
risks.

But Pfizer has doubtful any systematic couple between Zoloft
and birth defects and pronounced that a position is upheld by
individual medical groups including a American Heart
Association, American Psychiatric Association and American
College of Obstetricians and Gynecologists.

A counsel for plaintiffs did not immediately lapse requests
for comment.

Approved by a U.S. Food and Drug Administration, Zoloft is
part of a widely prescribed organisation of antidepressants famous as
selective serotonin reuptake inhibitors, or SSRIs.

In 2010, GlaxoSmithKline Plc paid an undisclosed
amount of income to settle some U.S. lawsuits joining another
SSRI, Paxil, to birth defects.

The subsequent Zoloft hearing is scheduled to take place after this
year in state justice in Philadelphia.

Article source: http://www.reuters.com/article/2015/04/17/pfizer-zoloft-idUSL2N0XE2JJ20150417

Scroll To Top